Wednesday, 18 Sep 2019

You are here

Herpes Zoster Increases the Risk of Stroke and MI

At the 2015 ACR annual meeting in San Francisco, Len Calabrese, DO, of the Cleveland Clinic, gave a plenary session talk linking "shingles" infection to an increased risk of CVA (see video).

These findings are underscored by a recent report from PLOS. Dr. Caroline Minassian and UK colleagues assessed the short-term increased risk of stroke and MI after zoster by examining 42,954 Medicare patiennts over age 65 years who had a shingles diagnosis and an ischemic stroke, and 24,237 patients with H. zoster and MI during a 5-year period.

Those infected with H. zoster had a 2.4 fold higher risk of an ischemic stroke and 1.7 times higher chance of MI in the first week after herpes zoster infection. This risk gradually decreased over time.

Vaccination against H. zoster did not effect the risks of ischemic stroke or MI.

These findings are important as 1 in 3 individuals in the general population will have a H. zoster in their lifetime, and the risk rises considerably after age 60 years.

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.